Diplopia and visual complaints in non-demented patients with Parkinson disease: a Japanese single center cross-sectional survey
Objective: To investigate the characterization of diplopia and visual complaints including minor forms of hallucinations (mHals) in non-demented patients with Parkinson disease (PD). Background: Double…Analysis of Levodopa Content in Commercial Formulations of Mucuna pruriens Seeds Used in Integrative Treatment of Parkinson’s Disease
Objective: Objective: Formulations of Mucuna pruriens (MP) seed products are readily available through the internet and health food stores, and are used by some Parkinson's…Difference in perception of the wearing-off between patients and physicians in Parkinson’s disease
Objective: To explore if any inconsistency exists in the perception of the presence of wearing-off (WO) symptoms between patients and physicians in Parkinson’s disease (PD).…THOR 201: A Proof-of-Concept Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of L-dopa delivered by Impel’s Precision Olfactory Delivery (PODTM) to Parkinson’s Disease Patients in an OFF Episode (in the presence of Dopa Decarboxylase Inhibitor)
Objective: Impel NeuroPharma has developed the patient-friendly, self or caregiver actuatedPrecision Olfactory Delivery (IMPEL PODTM) device to achieve consistent upper nasal cavity drug delivery, rapid…Laboratory Performance of the DopaFuse® Delivery System
Objective: SynAgile has developed the DopaFuse Delivery System to noninvasively and continuously administer levodopa/carbidopa (LD/CD) into the mouths of patients with Parkinson’s Disease (PD). The…STAT-ON: a Wearable Inertial System to Objectively Evaluate Motor Symptoms in Parkinson’s Disease
Objective: We present a wearable inertial system for the evaluation of motor symptoms in Parkinson's Disease. Background: PD is the second neurodegenerative disease affecting to around…A Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson’s Disease Complicated By “OFF” Episodes
Objective: To assess the effect of apomorphine sublingual film (APL130277; APL) on the QT interval in patients with Parkinson’s disease (PD) and “OFF” episodes participating…Effect of an Increase in Dose of Istradefylline, an A2A Receptor Antagonist, in Levodopa (LD)-Treated Patients with Parkinson’s Disease (PD)
Objective: To observe whether increasing the istradefylline dose from 20 to 40mg/day provides more patients with meaningful clinical responses. Background: Istradefylline, a well-tolerated selective adenosine…Does information from the Personal KinetiGraph™ (PKG) influence neurologists´ treatment decisions?
Objective: To evaluate if PKG data influences neurologists´ treatment decisions in routine clinical care of patients with Parkinson´s disease. Background: The PKG movement recording system is…A characterization of the ADL-level in daily life with Parkinson`s Disease based on objective measurements and subjective experiences.
Objective: 1. Test whether slow response to the medication and EMO-periods (Early Morning Off), affects the patient`s experience of being able to perform ADL-functions. 2.…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 24
- Next Page »